1) Has the FDA approval of adjuvant nivolumab impacted your practice volume? If so, can you estimate by how much. eg: 10% increase in volume
2) Compelling data supporting adjuvant BRAF/MEK was released at the same time. Though not yet FDA approved, I know many practices are already using.
Is your practice? IF so, has this too influenced your volume- and by how much?
Trying to get a sense of the overall impact of these incredible practice changing events (for providers).
In response to #1- I would say the approval has increased our volume more in terms of new patients coming for second opinions and I’m not quite sure why. I don’t know if it is because the community is uncomfortable recommending this or patients aren’t wanting to get treatment so they come hoping we won’t recommend anything. I would say I’ve noticed a small increase in the volume of returns as we put more patients on adjuvant nivolumab.
In response to #2- We are currently not recommending adjuvant BRAF/MEK.